香港科技探索(01137.HK)2023年一季度訂單總商品交易額約19.8億港元 按季下跌12.8%
格隆匯4月11日丨香港科技探索(01137.HK)公吿,截至2023年第一季度訂單總商品交易額約為19.8億港元,按季下跌12.8%。此跌幅為預期內,主要是由於於2022年2月期間消費者為應對第五波新型冠狀病毒疫情,以及香港可能實施"全民強制檢測"計劃和"禁足"的不確定性,而大量購買糧油雜貨及個人護理產品所致。
公司對香港電子商貿發展的增長動力持正面態度。這不僅是因為每日訂單總商品交易額維持增長方向,獨立客户數目亦持續上升,從2022年3月53.4萬名及2023年2月54.2萬名增至2023年3月56.7萬名。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.